Compare ROK & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROK | ONC |
|---|---|---|
| Founded | 1903 | 2010 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.3B | 34.8B |
| IPO Year | 1987 | N/A |
| Metric | ROK | ONC |
|---|---|---|
| Price | $401.62 | $302.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 12 |
| Target Price | ★ $392.00 | $369.50 |
| AVG Volume (30 Days) | ★ 1.0M | 284.8K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.67 | 0.58 |
| Revenue | ★ $8,342,000,000.00 | $4,972,687,000.00 |
| Revenue This Year | $6.95 | $895.40 |
| Revenue Next Year | $6.00 | $22.04 |
| P/E Ratio | ★ $52.83 | $545.67 |
| Revenue Growth | 0.94 | ★ 50.43 |
| 52 Week Low | $215.00 | $170.99 |
| 52 Week High | $415.89 | $385.22 |
| Indicator | ROK | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 59.40 | 34.89 |
| Support Level | $400.00 | $315.50 |
| Resistance Level | $415.89 | $326.77 |
| Average True Range (ATR) | 8.12 | 9.61 |
| MACD | -0.46 | -3.69 |
| Stochastic Oscillator | 49.98 | 9.35 |
With roots tracing back to the early 1900s, Rockwell Automation is the successor to Rockwell International, which spun off its avionics segment in 2001. It is a pure-play industrial automation company that operates through three segments. Its largest segment by revenue, intelligent devices, sells factory floor-level devices such as motors, drives, sensors, relays, and actuators. Its software and control segment sells visualization, simulation, and human-machine interface software and control products such as programmable controllers, computers, and operator terminals. Its smallest segment, lifecycle services, offers digital consulting, engineered-to-order services, and other outsourced services such as remote monitoring, cybersecurity, and asset and plant maintenance and optimization.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.